Introduction
Patients with symptoms suspected of coronary artery disease (CAD) often are referred for noninvasive cardiac imaging. Most require administration of stress agents and rely on detecting abnormal physiological response of coronary stenosis to stress. Although these tests perform well, significant limitations exist with regard to borderline findings. These often lead to another type of noninvasive testing and/or referral to invasive coronary angiography (ICA), which often shows absence of significant stenosis. A recent national registry showed that only 38% of patients without known CAD who underwent elective invasive angiography had obstructive coronary stenosis [1] .
The holy grail of assessing CAD has been the direct visualization of the coronary arteries. ICA and intravascular ultrasound remain the gold standards for detecting coronary stenosis and atherosclerotic plaques but carry significant costs and procedural risks. Therefore, the advent of noninvasive imaging techniques such as coronary computed tomography angiography (CCTA) capable of direct evaluation of coronary anatomy could have a huge impact in managing patients with suspected CAD.
Multiple large studies have confirmed the ability of calcium score by noncontrast cardiac computed tomography (CT) in providing prognostic value about future CAD events over and beyond the information provided by standard risk factors and have been extensively reviewed elsewhere [2 ] . Therefore, the main focus of this article is to review recent data on the diagnostic accuracy and prognostic value of contrast CCTA that establish the role of CCTA in management of patients with suspected CAD. In addition, strategies to reduce radiation exposure and the most recent recommendation by major cardiovascular societies with regard to the appropriate clinical applications of CCTA will be discussed. Finally, future challenges will be briefly discussed.
Technology and protocols
Until recently, the noninvasive imaging of the coronary arteries had been a challenge due to the small size and constant motion with the cardiac and respiratory cycles. Over the last decade, however, dramatic advances in both scanner and software technology have achieved adequate volume coverage, sub-millimeter spatial resolution and heart-freezing temporal resolution, which permit the accurate noninvasive depiction of both cardiac structures and the coronary vessels. At present, 64-detector row CT systems are the most widely employed platform for performing CCTA. These scanners are capable of image acquisition with high spatial resolution (0.5-0.6 mm isotropic resolution), good temporal resolution (83-200 ms), and sufficient Z-axis coverage (20-40 mm) to permit fast overall scan times (5-8 s), resulting in marked improvement of the evaluability of all coronary artery segments [3 ] . Newer multislice computed tomography (MSCT) scanners are capable of even greater spatial resolution (up to 0.23 mm in-plane resolution), higher temporal resolution (up to 75 ms via dual-source scanner and faster gantry speed technology), and enhanced volume coverage (up to 16 cm through 256 or 320-detector arrays), allowing completion of a study within one or two heart beats, all while significantly reducing radiation dose [4, 5] .
A slow and steady heart rate of less than 65 beats/minute (often with the administration of beta-blockers) is needed to optimize image quality. A low-energy scout film is acquired to ensure the scan range covers as closely as possible to the structures of interest to minimize radiation. Sublingual nitroglycerin is given to dilate the coronary arteries. Once intravenous contrast agent (4-7 ml/s) is administered via an 18-gauge or larger catheter placed preferably in the right antecubital vein, the initiation of ECG-gated image acquisition is started when a predetermined level of contrast opacification as determined by Hounsfield Unit (HU) is reached in the ascending aorta (signal of the arrival of intravenous contrast in the coronary arteries). Currently, depending on the scanner, two acceptable methods exist: automatic bolus tracking or the timing bolus method for determining the contrast transit time.
The entire CT data set, synchronized to the ECG, is acquired employing either one of two different modes: retrospective gating or prospective gating. Retrospective ECG gating mode is performed with helical acquisition (patient/table is continuously advanced during the gantry rotation) with the X-ray tube turned on throughout the cardiac cycle [6] . Data from the most motion-free phase (usually mid-diastole) are then reconstructed for analysis. Advantages include the ability to reconstruct alternate phases in case of cardiac motion artifact and the ability to perform functional analysis such as wall motion and ejection fraction. Due to its spiral mode of acquisition with the X-ray tube turned on throughout the cardiac cycle, a significant radiation dose has been its main limitation. By contrast, prospective ECG triggering or step and shoot mode involves axial acquisition (table intermittently advances, usually every other two to three beats) with the X-ray tube on only for a prespecified period of the cardiac cycle (usually mid-diastole) [7] . As only a small portion of the cardiac cycle is imaged, additional image reconstruction in different phases of cardiac cycle in case of motion artifact is limited and functional analysis is not possible. However, it is associated with a significant reduction in radiation dose (close to 80% reduction as compared with retrospective gating mode) [8] with no reduction in diagnostic performance [9] .
Limitations
There are several limitation with CCTA. Patients unable to cooperate with scanning instructions should be considered for other imaging modalities. Uncontrollable arrhythmias can result in significant motion artifacts and multiple uninterpretable coronary segments [10 ] .
Contraindications to iodinated contrast use include pregnancy, prior severe/anaphylactic contrast reaction, and renal insufficiency (but end-stage renal disease is not a contraindication) for contrast-induced nephropathy [11] . Certain conditions should raise concerns for the use of prescan beta-blocker (chronic obstructive pulmonary disease/asthma, decompensated heart failure, and advanced atrioventricular block) and nitroglycerin (severe aortic stenosis, hypertrophic cardiomyopathy, recent phosphodiesterase-5 inhibitor use). The presence Finally, the use of ionizing radiation should also be taken into consideration before ordering a CCTA.
Diagnosis of coronary artery disease
Stenosis detection is currently the leading indication/ application for performing CCTA ( Fig. 1) and is supported by excellent results from numerous single-center [12] [13] [14] [15] [16] [17] [18] [19] [20] and three multicenter studies [21] [22] [23] using different scanner technologies (Table 1 ) [21] [22] [23] in symptomatic patients with suspected CAD. CCTA is notable for its diagnostic accuracy with a very high sensitivity and negative predictive value superior to other noninvasive cardiac testing for the detection of significant coronary stenosis. More importantly, its excellent negative predictive value effectively rules out the presence of obstructive CAD (Fig. 2) . Therefore, it is optimal at identifying patients who would not benefit from ICA. However, the specificity and positive predictive value are not ideal. Spatial resolution limits the ability of CTA to provide exact, quantitative measures of stenosis severity when compared with ICA. As discussed earlier, heavily concentrically calcified segments have blooming artifact causing nondiagnostic study (Fig. 3 a) or overestimation of stenosis severity. Finally, segments affected by arrhythmia ( Fig. 3 b) , cardiac or respiratory motion, small vessel size, image noise, or overlap by other structures are frequently difficult to evaluate accurately.
Coronary stent patency is readily assessable by the presence of contrast in the segments distal to the stent. Absence of contrast is highly suggestive of severe in-stent restenosis (ISR) or occlusion. On the contrary, accurate assessment of degree of ISR is challenging due to high attenuation of the stent material with resulting blooming and beam-hardening artifact that can obscure the lumen and is highly dependent on stent diameter. A recent meta-analysis showed a pooled sensitivity of 0.84 and specificity of 0.91 and concluded that the diagnostic role of CCTA as an alternative to ICA for ISR remains limited [24] . The consensus suggests that CCTA may be a reasonable alternative to invasive angiography to rule out significant ISR only in patients at low-to-intermediate pretest probability for ISR and who are known to have 3 mm or larger stents, providing high image quality is anticipated. On the contrary, imaging of venous bypass grafts is less challenging because of larger size and relatively motionless nature [25] . CCTA can achieve a sensitivity and specificity of 95% or higher for the detection of venous graft occlusion or stenosis [26] .
Imaging of left internal mammary artery grafts can in some cases be more difficult because of artifacts caused by metal clips placed alongside the bypass grafts. However, the ability to assess the native coronary arteries in patients post coronary artery bypass graft (CABG) is limited due to the generally severe underlying coronary calcification and small size.
Detection and characterization of coronary atherosclerotic plaque
Current CT technology has demonstrated the feasibility of CCTA to detect, characterize and quantify nonobstructive coronary plaque in selected high-quality images, which could have important implication in cardiac risk stratification and management. A large percentage of myocardial infarctions (MI) occur in previously asymptomatic individuals with nonobstructive lesion [27] . Less calcified lesions are often noted in patients with acute MI than in those with stable angina [28] . In addition, positive remodeling, higher prevalence of either spotty calcification or exclusively noncalcified plaque, and higher plaque volume but not the degree of stenosis differentiate culprit lesions from nonculprit lesions in acute coronary syndrome (ACS) patients and also in patients with stable angina [29, 30] .
Overall, when compared with intravascular ultrasound, attenuation-based plaque characterization by CCTA has good correlation for proximal coronary segment plaque assessment [12] . The accuracy for the detection of calcified plaque is significantly higher than for noncalcified plaque. However, further characterization of noncalcified plaque into fibrous or lipid-rich plaque based on Hounsfield Unit is currently challenging due to substantial overlap of attenuation range [31] . Factors such as slice thickness, volume averaging, and lumen contrast density could affect the measurement of plaque attenuation, with higher density seen for thicker slices and denser luminal contrast. At this stage, plaque assessment remains experimental; therefore, its clinical utilization is not warranted.
Prognostic value of coronary computed tomography angiography
The prognostic value of CCTA for predicting clinical events has been less defined, until recently [32] . In a large study of 1127 patients with chest pain symptoms, measures of noninvasive angiographic disease extent, location, and distribution detected by three distinct CCTA grading systems significantly predicted the risk of all-cause death [33] . A subsequent study of 2076 patients showed that the CAD severity [hazard ratio 3.02; 95% confidence interval (CI) 1.89-4.83), every 10% reduction in left ventricular ejection fraction (LVEF) (hazard ratio 1.47; 95% CI 1.17-1.86), and total plaque score (hazard ratio 1.17; 95% CI 1.06-1.29) on 64 slices CCTA provided incremental value over clinical predictors in predicting all-cause mortality and nonfatal MI. Absence of obstructive CAD confers an excellent prognosis, with an annual event rate of only 0.4% [34 ] . The long-term predictive value was shown in 2538 patients studied by contrast-enhanced Electron Beam CT (EBCT) followed for up to 15 years (mean 78 AE 12 months). The presence of coronary lesions was predictive of mortality above and beyond traditional risk factors. The risk-adjusted hazard ratios for CTA-diagnosed CAD were 1.7, 1.8, 2.3, and 2.6-fold for three-vessel Automatically generated curved (a) and straight (b) multiplanar reformation of the right coronary artery and three-dimensional volume rendering of the left coronary system (c) show normal coronary arteries. The high negative predictive value of a normal coronary computed tomography angiogram reliably excludes coronary artery stenosis as a reason for chest pain and predicts an excellent cardiac outcome.
nonobstructive, one-vessel obstructive, two-vessel obstructive, and three-vessel obstructive CAD, respectively (P > 0.0001), when compared with the group who did not have CAD [35] . A recent systematic review/metaanalysis evaluated 18 longitudinal studies with 9592 patients (median follow-up of 20 months). A normal CCTA conveys an excellent prognosis for symptomatic patients, with annualized event rate of less than 0.2% (none cardiac), which is comparable to the background event rate among healthy low-risk individuals [36 ] . For patients with nonobstructive lesion, the event rates are higher than for those without any disease. Increasing cardiovascular events (MI and revascularization) and all-cause mortality were seen with increasing severity of CAD. The pooled annualized event rate for obstructive (any vessel with >50% luminal stenosis) versus normal CCTA was 8.8 versus 0.17% per year for major adverse cardiac events (P < 0.05) and 3.2 versus 0.15% for death or MI (P < 0.05; Fig. 4) [36 ] . One caveat of these studies is the verification bias; namely, patients with obstructive lesion on CCTA are more likely to undergo invasive angiogram and subsequent revascularization.
In addition to its prognostic value in stable patients, prognostic data on acute chest pain patients are also emerging. In a small study, sensitivity of CCTA for predicting major adverse cardiovascular events (death, myocardial infarction, or revascularization) during hospitalization and follow-up was 92% and specificity was 76%. Although the positive predictive value was only 52%, the negative predictive value was 97%. The high negative predictive value for excluding ACS and low event rate are potentially very useful in decreasing the number of unnecessary hospital admissions [18] .
In conclusion, CCTA offers prognostic value comparable with other functional stress testing modalities. Long-term follow-up studies using current generation multidetector computed tomography will help to cement its role in Percentage of annualized event rates for combined major adverse cardiac events (MACE), death (all-cause), myocardial infarction (MI), and revascularization (Revasc), stratified by cardiac computed tomography angiography diagnosis of no coronary artery disease (CAD), nonobstructive CAD (<50% stenosis), and obstructive CAD (>50% stenosis). All groups were significantly different by analysis of variance (P < 0.05). Adapted with permission from [36 ] .
the management of patients with symptoms suggestive of CAD.
Radiation dose reduction strategies
Recent publications have raised concerns over radiation exposure from diagnostic imaging tests, including cardiac CT [37] [38] [39] . A recent international multicenter study showed large variations in effective radiation does (5-30 mSv) among different centers. The difference depends on the scanner manufacturer and use of radiation reduction protocols [40] .
Achieving images of diagnostic quality while adhering to ALARA (As Low As Reasonably Achievable) requires careful patient selection/preparation and scanning techniques. Several strategies exist for effective radiation dose (ERD) reduction using any current 64-MSCT scanners without need for any new upgrade. Newer hardware/software and imaging protocols can dramatically reduce the amount of total ERD (comparable to or lower than ICA and nuclear perfusion imaging).
(1) Limit the scan field of view to address the clinical question and include noncardiac structures only as indicated. (2) Reduce the peak mAs in relation to the body size of the patient. A visual estimate of noise on the noncontrast scan can be used to help predict mAs needed for an acceptable quality scan. (3) Use ECG-dependent current modulation to reduce the tube current in systole. Peak mAs is applied to a very short time in mid-diastole for coronary evaluation (70-75% phase of cardiac cycle). As scanning is performed throughout the cardiac cycle, data acquired are sufficient for regional wall motion/ LVEF assessment [41, 42] . The lower and more regular the heart rate, the greater is the relative dose reduction. (4) Reduce the kV setting for smaller size patients. ERD decreases by the square of the kV reduction. CCTA performed at 100 kV in smaller size patients can achieve ERD reduction of 53% compared with traditional 120 kV, while maintaining diagnostic image quality [41, 43] . Compared with standard tube voltage (100 or 120 kVp for BMI <25 or 25-35 kg/m 2 , respectively), a reduced tube voltage protocol (80 or 100 kVp) results in lower ERD (2.6 versus 1.3 mSv) with comparable diagnostic performance using ICA as gold standard [44 ] . (5) Prospective ECG-gated scanning mode offers similar image quality and substantially reduced ERD compared with retrospective gating. A large study demonstrated an 83% reduction in ERD with prospective gating compared with retrospective gating (2.8 versus 18.4 mSv) with similar image quality [45] .
(6) Latest advances in dose reduction methods include statistical iterative reconstruction algorithm and the high-pitch spiral CT acquisition available on the latest generation 128 slices dual source scanner. The sequence uses high pitch (over 3) and fast table speed to perform image acquisition for the entire volumetric data set of the heart within a single cardiac cycle. The entire period of data acquisition is approximately 260 ms long and is placed in diastole. In patients with weight below 100 kg, this scan protocol provides high image quality at very low ERD of less than 1 mSv [5, 46] .
In summary, while prospective gating mode is used with tube current/voltage adjusted to patient's size, a CCTA can be routinely performed with an ERD of 3 mSv or less with the current generation 64 slices scanner. This dose is very close to the background radiation received by the general US population (The National Commission on Radiological Protection report on ionizing radiation exposure of the population of the United States. NCRP publication number 160; http://www.ncrponline.org).
With the advent of the newest dual-source computed tomography scanner, it is now possible to obtain a diagnostic CCTA with less than 1 mSv (close to dose of screening mammogram) [47] .
Appropriate clinical application
In view of rapidly developing technology and clinical use, a guideline for clinical indications and appropriateness for CCTA was clearly needed to avoid indiscriminate and inappropriate use. The first outline was produced in 2006 by the American College of Cardiology Foundation (ACCF) together with several other key specialty and subspecialty societies. The large amount of clinical data accumulation led to an update in late 2010 [48, 49 ] .
The document includes 93 common and important clinical scenarios developed by a writing group and then scored by a separate technical panel. In total, 35 were judged to be appropriate, and 58 were either inappropriate or uncertain. The main appropriate indications for CCTA as outlined in the updated appropriateness criteria are listed below Due to its extremely high negative predictive value, there is consensus that CCTA is considered appropriate as a first test in individuals with symptoms, sex, and age suggestive of low-to-intermediate probability of CAD (Fig. 1) . A normal computed tomography angiography essentially rules out presence of obstructive CAD (Fig. 2) . This applies to both patients with nonacute symptoms and those with suspicion of ACS.
Recently, CCTA is increasingly being used for acute chest pain due to imperfection of clinical models in predicting presence of ACS. It has shown good positive predictive value for diagnosing ACS (Fig. 5) . A negative study is associated with an extremely low event rate [18] , allowing rapid triage and reducing the number of unnecessary hospital admissions [19] . It is very comparable to the traditional management with nuclear stress myocardial perfusion imaging, with shorter emergency department (ED) stay and lower cost [17] . repetitive testing or referral to ICA, which often reveals absence of obstructive disease. The extremely high negative predictive value makes CCTA extremely useful in management of these patients. It obviates need for subsequent costly testing or unnecessary treatment in those without evidence of CAD. Furthermore, even presence of nonobstructive plaque detected by CT establishes the diagnosis of CAD and could potentially help the physician and patient in pursuing aggressive secondary prevention that could halt the disease progression.
In addition, CCTA was also considered appropriate in place of ICA in patients with reduced LVEF at low or intermediate pretest probability of disease or those undergoing noncoronary cardiac surgery.
Stent evaluation with CCTA was felt to be appropriate only with left main stents and uncertain with large stents (! 3 mm in diameter) after long time periods (! 2 years).
Due to its excellent spatial resolution and threedimensional dataset, evaluation of cardiac structure and function is also a major strength of CT. Currently, CCTA is considered the test of choice for assessment of coronary anomalies due to its ability to accurately delineate the course of anomalous vessels and its three-dimensional relationship with other cardiac structures (Fig. 8) . Also considered appropriate are evaluation of major congenital heart disease, right and left ventricular function, prosthetic heart valves, and LVEF when the results of other modalities are nondiagnostic [48, 49 ].
Asymptomatic persons
The 2010 ACCF/AHA Guideline In contrast, both the guideline and the appropriateness criteria consider that CCTA is not recommended or appropriate for cardiovascular risk assessment in asymptomatic adults.
Coronary computed tomography angiography Chang et al. 399 Figure 6 Coronary computed tomography angiography in a 52-year-old woman presented with acute atypical chest pain
Adenosine myocardial perfusion single-photon emission computed tomography revealed anterior reversible defect (a) with suspected breast attenuation artifact. Curved multiplanar reformation of the coronary computed tomography angiography (b) shows normal coronary arteries, obviating need for further work-up for coronary artery disease. Note the presence of a large hiatal hernia (c) as potential cause of her symptom.
Despite the attractive ability to detect both calcific and supposedly higher-risk noncalcific plaques, very few data are available on the role of CCTA for risk assessment in asymptomatic persons. In a study of 1000 middle-aged asymptomatic persons undergoing CCTA for general health evaluation, only 4% had purely noncalcific plaque (CACS of 0). During the 17 months of follow-up, only 15 patients had cardiac events. However, 14 of these were revascularization prompted by the CCTA results. Due to the very small number of hard clinical events, it was impossible to determine the incremental prognostic values of CCTA results over the clinical risk assessment information [50] .
At this stage, due to the paucity of benefit data and the potential concern of radiation exposure and increasing healthcare cost, it is logical to conclude that CCTA should not be used for screening asymptomatic persons.
Future direction and challenges
As cardiac CT technology evolves and more clinical data are accumulated, the clinical applications will continuously expand beyond diagnosis and prognosis of CAD. This powerful noninvasive imaging technique allows, in one single study, comprehensive assessment of coronary anatomy (degree of stenosis, detection and characterization of coronary artery plaques burden) and integrating the left ventricular morphology, function, perfusion, and viability.
This will eventually change the traditional way physicians manage patients with risk of developing CAD, suspected CAD and known CAD. The constant development of new system and acquisition/processing strategies should ameliorate the concerns over the radiation with CCTA. Furthermore, favorable data on cost-effectiveness of incorporating CCTA into the diagnostic algorithm of CAD are rapidly accumulating [17, 51] .
However, there are no published controlled studies that evaluate the beneficial impact of specific therapy (medical or procedural) on clinical outcome in patients identified as having CAD by CCTA. In a changing healthcare environment, the best way to incorporate CCTA among other imaging modalities into daily clinical care to achieve a cost-effective healthcare delivery needs to be better studied and defined. Therefore, the updated appropriate use criteria serve as a guideline for good clinical practice and the rational use of this technology to avoid overutilization of CCTA, and also point toward areas in need of further research to provide the greatest benefit to patients and society. 
